title: Better adherence to antihypertensive agents and risk reduction of chronic heart failure.
abstract: OBJECTIVE
  Antihypertensive (AH) agents have been shown to reduce the risk of major cardiovascular events including chronic heart failure (CHF). However, the impact of changes in patterns of AH agents use on CHF is unknown. Our objective was to estimate to which different patterns of AH agent use is associated with the occurrence of CHF in a population-based study.
  
  
  RESULTS
  A cohort of 82 320 patients was reconstructed using the Régie de l'assurance maladie du Québec's databases. Patients were eligible if they were between 45 to 85 years of age, had no indication of cardiovascular disease and were newly treated with AH therapy between 1999 and 2004. A nested case-control design was used to study the occurrence of CHF. Every case of CHF was matched for age and duration of follow-up to a maximum of 15 randomly selected controls. Adherence level was reported as a medication possession ratio. Conditional logistic regression models were used to estimate the rate ratio (RR) of CHF adjusting for different covariables. The mean patient age was 65 years, 37% were male, 8% had diabetes, 19% had dyslipidaemia and mean time of follow-up at 2.7 years. High adherence level (95%) to AH therapy compared with lower adherence level (60%) was associated with an additional reduction of CHF events (RR: 0.89; 0.80-0.99). Risk factors for CHF were being on social assistance, diabetes, dyslipidaemia, higher chronic disease score and developing a cardiovascular condition during follow-up.
  
  
  CONCLUSIONS
  Our study suggests that a better adherence is associated with a significant risk reduction of CHF. Adherence to AH therapy needs to be improved to optimize benefits.
authors.affiliation: Faculty of Pharmacy, University of Montreal, Montréal, QC, Canada. sylvie.perreault@umontreal.ca
authors.forename: S
authors.initials: S
authors.lastname: Perreault
authors.forename: A
authors.initials: A
authors.lastname: Dragomir
authors.forename: M
authors.initials: M
authors.lastname: White
authors.forename: L
authors.initials: L
authors.lastname: Lalonde
authors.forename: L
authors.initials: L
authors.lastname: Blais
authors.forename: A
authors.initials: A
authors.lastname: Bérard
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002170:Canada; D016022:Case-Control Studies; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality; D016208:Databases, Factual; D005260:Female; D006333:Heart Failure / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011634:Public Health / Q000706:statistics & numerical data; D040242:Risk Reduction Behavior; D016903:Drug Monitoring
chemical_list: D000959:Antihypertensive Agents